Copyright medicaldialogues
Ahmedabad: Zydus Lifesciences has announced that the company has received the Establishment Inspection Report (EIR) from the U.S. Food and Drugs Administration (USFDA) for an inspection conducted at its manufacturing facility located at Baddi from 4th to 13th August 2025. In August, the company received four observations.Read also: Zydus Lifesciences gets 4 USFDA observations for Baddi plantThe EIR has classified the facility as Voluntary Action Indicated (VAI). The USFDA has concluded this inspection as closed.Read also: Zydus bags Health Canada approval for Mesalamine suppositories for active ulcerative proctitisZydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs.
